Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:06

Coagulation

1.4K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.4K
Coagulation01:09

Coagulation

10.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
10.5K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

3.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.3K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

772
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
772
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

605
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
605
Transcription Factors02:16

Transcription Factors

82.8K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
82.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfer of Emicizumab into Breast Milk in Postpartum Acquired Hemophilia A.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins.

Research and practice in thrombosis and haemostasis·2026
Same author

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis.

Haematologica·2025
Same author

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.

Blood advances·2025
Same author

Anti-CD19 CAR-T cell therapy for acquired hemophilia A.

Leukemia·2025

Related Experiment Video

Updated: Feb 5, 2026

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K

Pharmacodynamic Interaction Between Emicizumab and Coagulation Factor VIII.

Matthias Chill1, Emma Louise Konarski1, Annika Klingberg1

  • 1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Thrombosis and Haemostasis
|February 3, 2026
PubMed
Summary

Emicizumab and Factor VIII (FVIII) show a synergistic effect, enhancing blood clotting at low FVIII concentrations. This interaction, crucial for hemostasis, diminishes as FVIII levels increase beyond 20 IU/dl.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.2K

Related Experiment Videos

Last Updated: Feb 5, 2026

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.2K

Area of Science:

  • Hematology
  • Pharmacology
  • Biochemistry

Background:

  • Emicizumab, a bispecific antibody, mimics activated Factor VIIIa (FVIIIa) to aid Factor IXa in activating Factor X.
  • Emicizumab's lower affinity for FIX/IXa and FX compared to FVIIIa suggests FVIII might displace it at higher concentrations.
  • The interaction between emicizumab and FVIII at low concentrations remains poorly understood.

Purpose of the Study:

  • To investigate the pharmacodynamic interaction between emicizumab and FVIII.
  • To evaluate additivity and synergy between emicizumab and FVIII using thrombin generation as a marker.

Main Methods:

  • Tissue factor-triggered thrombin generation assays were performed.
  • FVIII-deficient plasma was supplemented with varying concentrations of emicizumab and recombinant FVIII, alone and in combination.
  • Thrombin generation served as a quantitative measure of hemostatic capacity.

Main Results:

  • A synergistic interaction was observed between emicizumab and FVIII.
  • This synergy significantly enhanced endogenous thrombin potential and peak thrombin generation.
  • The synergistic effect was prominent at low FVIII concentrations (below 20 IU/dl) and disappeared at higher levels.

Conclusions:

  • Emicizumab and FVIII exhibit synergy, explaining emicizumab's efficacy at low FVIII levels.
  • This interaction provides a framework for assessing novel non-factor therapies with intrinsic FVIII.
  • Pharmacodynamic synergy is key to understanding emicizumab's hemostatic effects in specific patient populations.